<article>China-based drug manufacturer <a style="color: #333399;" href="http://www.jilinzixin.com.cn" target="_blank">Jilin Zixin Pharmaceutical Co Ltd</a> (Zixin Pharma) is investing up to $42 million in <a style="color: #333399;" href="http://nabsys.com" target="_blank">Nabsys 2.0</a>, a high definition whole genome mapping company in the US.</article>

China-based drug manufacturer <a style="color: #333399;" href="http://www.jilinzixin.com.cn" target="_blank">Jilin Zixin Pharmaceutical Co Ltd</a> (Zixin Pharma) is investing up to $42 million in <a style="color: #333399;" href="http://nabsys.com" target="_blank">Nabsys 2.0</a>, a high definition whole genome mapping company in the US.
Zixin Pharma board signed a share purchase agreement with Nabsys 2.0 to acquire 67 per cent stake of the American firm.
Zixin Pharma will pay Nabsys 2.0 an initial capital of $6 million.
Nabsys 2.0 is registered in Delaware limited liability company, the legal representative for Barrett Bready, concurrently Brown University.
Nabsys uses solid-state nanodectors to build whole genome maps with sub-diffraction-limit resolution that are truly high definition, its website said. These maps offer compelling advantages for the analysis of structural variation, the assembly of genomes, and as a way of confirming putative variants called using other technologies.
The deal is part of Zixin Pharma&#8217;s business expansion in the global market, specifically the US market.
Founded in 1998, Zixin Pharma is principally engaged in the manufacture and sale of traditional Chinese patent drugs, as well as the plantation of medicinal materials.
The company’s products include treatment of cardiovascular and cerebrovascular diseases, digestive system diseases and bone fracture.
Also Read:
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/ifc-might-invest-19m-in-essex-bio-47205/" target="_blank">China: IFC may inject $19m into HK-listed Essex Bio-Technology</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/china-biologic-products-announces-secondary-offering-commonstock-43143/" target="_blank">China Biologic announces secondary offering of common stock; Warburg Pincus makes partial exit</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/42448-temasek-regeneron-42448/" target="_blank">Singapore: Temasek increases stake in Regeneron Pharmaceuticals</a>

China's Zixin Pharma acquires 67% stake in US genomics firm Nabsys for $42m

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

China's Zixin Pharma acquires 67% stake in US genomics firm Nabsys for $42m

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief